Recent results from a Phase I clinical trial (NCT04555551) of CAR‐T cell therapy (MCARH109) targeting GPRC5D confirmed that GPRC5D is an important immunotherapeutic target in multiple myeloma.237. This evidence concerns the gene GPRC5D and plasma cell myeloma.